echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Meet next 6 years, what does new drug research and development rely on?

    Meet next 6 years, what does new drug research and development rely on?

    • Last Update: 2015-12-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: bioprospecting 2015-12-22 drug discovery and development is the key first part of the long march of commercialization for pharmaceutical companies and biotechnology companies With more and more patients' symptoms and syndromes being diagnosed, drug development process is very important in the process of new drug development and recommendation Drug research and development is a long process, including target identification, target confirmation, clinical trials, registration applications, etc According to the report released by research and markets, an international well-known business consulting company, the average time from target identification to application for registration is 15 years In the next six years, new drug R & D depends on the regulatory level and speed of policy and government agencies to play a crucial role in new drug approval How to make new drug approval and review more smooth and reduce the time cost, and encourage data sharing from the system can promote the rise of regulatory level In addition, how to reduce taxes, reduce export tariffs of instruments and equipment, encourage government and private investment, and make laws to favor low-cost drugs and new target drugs are all countermeasures to promote new drug research and development In the next six years, drug research and development depends on drug awareness On the one hand, North American companies have the largest market for drug discovery in the world Some mainstream new drug research and development technologies and service providers are concentrated in the United States The complete and advanced factory infrastructure and research laboratory equipment are the important driving force of new drug research and development On the other hand, North America has the largest brand patent drug market in the world The assistance of government management system and residents' drug use literacy (awareness) are another driving force for us pharmaceutical companies to strive to develop new targeted drugs In contrast, European residents are more cautious in drug use, so their motivation is less than that of North America In the next six years, new drug R & D depends on services According to the research and markets report, between 2015 and 2021, new drug R & D is inseparable from biological services, chemical services, pharmaceutical services, drug metabolism and pharmaceuticals services (DMPK) ) Encouraged by EU policies, the R & D ecosystem in Europe is developing in a favorable direction Chinese, Japanese and Indian enterprises are still providing contract outsourcing services (CRO) for western large pharmaceutical companies China has gradually become the leader of cro services in Asia, with the international pharmaceutical companies building their production bases in China In the next 6 years, the new drug research and development report by science and technology Research and Markets pointed out that the development of Science (proteomics, genomics, bioinformatics) will become an important cornerstone of new drug research and development; Technology (qPCR, chromatography, mass spectrometry, DNA& protein microarray, high throughput sequencing, microfluidics, gel electrophoresis, protein & amp; Nucleic acid separation is the main tool for new drug research and development; in addition, some emerging technologies such as back scattering interferometry, cantilever array and so on will bring more creativity for new drug research and development In the next six years, new drug R & D depends on the following enterprises according to the analysis of research and markets report In 2015-2021, global new drug R & D will mainly focus on Albany molecular research, AstraZeneca, Bayer, bohringeringheliem, Charles River Laboratories, Covance, cyprotex, Eli lily, EVT innovation, Gen script GlaxoSmithKline, Johnson and Johnson, Pfizer, pharmaceutical product development (PPD), quintiles, Sanofi, viva biotechnology, wil research laboratories, Wuxi Apptech.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.